{"doi":"10.1016/j.crad.2022.09.124","title":"The frequency of change in five-point scale score with a Bayesian penalised likelihood PET reconstruction algorithm on interim FDG PET-CT and its potential implications for therapy decisions in Hodgkin's lymphoma","abstract":"Aim To assess the effect of a Bayesian penalised likelihood (BPL) reconstruction algorithm on the five-point scale (5-PS) score, response categorisation, and potential implications for therapy decisions after interim 2-[ 18 F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography (PET)–computed tomography (CT) (iPET-CT) to guide treatment in classical Hodgkin's lymphoma (HL). Materials and methods The present study included new patients with HL undergoing iPET-CT from 2014–2019 after two cycles of doxorubicin (Adriamycin), bleomycin, vincristine, and dacarbazine (ABVD). Two reporters categorised response using the 5-PS and measured maximum standardised uptake values (SUV max ) of the most avid tumour residuum, mediastinal blood pool, and normal liver with ordered subset expected maximisation (OSEM) and BPL reconstructions. Results Eighty-one iPET-CT examinations were reviewed. Compared with OSEM, BPL increased the 5-PS score by a single score in 18/81 (22.2%) patients. The frequency of potential treatment intensification by changing a score of 3–4 was 13.6% (11/81) and represented 25% (11/44) of patients with a score of 3 on OSEM. All 11 patients remained in remission without a change in therapy (mean 63 months) except one who required second-line treatment for refractory disease. Median SUV max of tumour residuum was significantly higher with BPL compared with OSEM (2.7 versus 2.4, p<< 0.0001), whilst liver SUV max was significantly lower for both reporters (up to 6.6%, p< 0.0001). Conclusion BPL PET reconstruction increased the 5-PS score on iPET-CT in 22% of HL patients and can potentially result in unnecessary treatment escalation in over half of these patients.","journal":"Clinical Radiology","year":2022,"id":312785,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9615,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1011081,"name":"Hajira Ilyas","orcid":null,"position":1,"is_corresponding":false},{"id":1010642,"name":"Joel Dunn","orcid":"0000-0002-0936-9993","position":2,"is_corresponding":false},{"id":1010643,"name":"Nida Mir","orcid":"0000-0001-8388-657X","position":3,"is_corresponding":false},{"id":1011082,"name":"Amanda Duran","orcid":null,"position":4,"is_corresponding":false},{"id":1010644,"name":"N. George Mikhaeel","orcid":"0000-0003-0359-0328","position":5,"is_corresponding":false},{"id":1010645,"name":"Sally F. Barrington","orcid":"0000-0002-2516-5288","position":6,"is_corresponding":false},{"id":1010641,"name":"Manil Subesinghe","orcid":"0000-0002-5688-0153","position":0,"is_corresponding":true}],"reference_count":38,"raw_metadata":null,"created_at":"2026-07-19T00:33:40.460845Z","pmid":"36333130","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}